Robyn L. Woods BSc (Hons), PhD, is an Associate Professor in the School of Public Health and Preventive Medicine, Monash University, Alfred Hospital campus. She was the Director of the aspirin primary prevention clinical trial, ASPREE (ASPirin in Reducing Events in the Elderly), which was conducted in Australia and the United States from 2010 to 2017. It was the largest clinical trial to be conducted in Australia, recruiting 16,703 participants aged 70+ years, across South-Eastern Australia. She was the original Director (2018-2021) of the observational follow-on cohort study, ASPREE-XT, conducted from 2018 to 2024 to examine further factors contributing to aging health including legacy effects of aspirin. She is the Director of the large ancillary study, the ASPREE Healthy Ageing Biobank, and is currently the Australian principal investigator of the NIH-funded ASPREE-XT-Microbiome project (2020-2025). She was the co-first author of the primary New England Journal of Medicine paper (2018) describing the ASPREE results that changed clinical guidelines for preventative aspirin use in older persons. In 2005,  A/Prof Woods was awarded the Howard Florey Medal for her contributions to animal welfare and ethics, and she received the President's Award from the National Heart Foundation for services to the peer review processes in Australia.  She has more than 260 research publications with an H-index of 37.